FATE [NASD]
Fate Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.44 Insider Own1.40% Shs Outstand96.34M Perf Week-0.08%
Market Cap2.06B Forward P/E- EPS next Y-3.77 Insider Trans-22.90% Shs Float95.31M Perf Month-33.12%
Income-232.80M PEG- EPS next Q-0.83 Inst Own- Short Float17.37% Perf Quarter-37.35%
Sales63.10M P/S32.72 EPS this Y-6.40% Inst Trans1.03% Short Ratio11.87 Perf Half Y-55.83%
Book/sh6.57 P/B3.61 EPS next Y-28.50% ROA-24.60% Target Price86.26 Perf Year-69.59%
Cash/sh6.59 P/C3.60 EPS next 5Y- ROE-33.30% 52W Range20.49 - 97.43 Perf YTD-59.44%
Dividend- P/FCF- EPS past 5Y-16.30% ROI-32.00% 52W High-75.64% Beta1.76
Dividend %- Quick Ratio7.70 Sales past 5Y66.20% Gross Margin- 52W Low15.81% ATR2.79
Employees449 Current Ratio7.70 Sales Q/Q65.80% Oper. Margin- RSI (14)37.50 Volatility11.22% 10.41%
OptionableYes Debt/Eq0.00 EPS Q/Q-41.30% Profit Margin- Rel Volume0.84 Prev Close22.64
ShortableYes LT Debt/Eq0.00 EarningsMay 04 AMC Payout- Avg Volume1.39M Price23.73
Recom1.70 SMA20-18.07% SMA50-29.88% SMA200-53.82% Volume1,177,554 Change4.81%
Feb-11-22Resumed BMO Capital Markets Market Perform $50
Dec-15-21Upgrade Wedbush Neutral → Outperform
Dec-07-21Initiated Cowen Outperform
Nov-09-21Upgrade Citigroup Neutral → Buy $94 → $87
Aug-26-21Initiated Morgan Stanley Equal-Weight $77
Jun-07-21Upgrade H.C. Wainwright Neutral → Buy $120
May-07-21Upgrade Wedbush Neutral → Outperform $88
Apr-26-21Resumed Jefferies Buy $145
Feb-26-21Initiated BofA Securities Buy $115
Feb-26-21Downgrade Wedbush Outperform → Neutral
Feb-11-21Downgrade Citigroup Buy → Neutral
Jan-27-21Resumed H.C. Wainwright Neutral $108
May-13-20Initiated H.C. Wainwright Buy $42
Mar-04-20Initiated Barclays Overweight $40
Jan-09-20Downgrade BMO Capital Markets Outperform → Market Perform $22
Dec-30-19Reiterated Mizuho Buy $27 → $33
Dec-09-19Upgrade Wells Fargo Market Perform → Outperform
Nov-12-19Initiated SunTrust Buy $25
Nov-06-19Downgrade Wells Fargo Outperform → Market Perform
Oct-01-19Initiated Stifel Buy $27
May-09-22 07:32AM  
May-06-22 04:01PM  
May-05-22 10:18AM  
May-04-22 05:15PM  
04:01PM  
Apr-27-22 03:03PM  
Apr-25-22 06:04PM  
Apr-22-22 08:00AM  
Mar-30-22 11:30AM  
Mar-02-22 04:01PM  
Mar-01-22 11:59AM  
Feb-28-22 05:45PM  
04:01PM  
Feb-20-22 12:47AM  
Feb-16-22 08:00AM  
Feb-06-22 03:52PM  
Feb-02-22 01:38PM  
08:00AM  
Jan-27-22 09:38AM  
Jan-10-22 08:00AM  
Dec-23-21 01:38PM  
Dec-22-21 12:15AM  
Dec-19-21 06:24PM  
Dec-17-21 11:38PM  
Dec-14-21 07:35AM  
Dec-13-21 04:38PM  
04:31PM  
09:01AM  
Dec-08-21 08:06PM  
05:44PM  
Dec-01-21 08:00AM  
Nov-25-21 05:57AM  
Nov-11-21 08:00AM  
Nov-09-21 09:00AM  
Nov-05-21 09:24AM  
Nov-04-21 05:15PM  
04:01PM  
09:01AM  
Oct-28-21 03:06PM  
Oct-25-21 08:00AM  
Oct-12-21 05:37AM  
Oct-01-21 08:01AM  
Sep-15-21 08:00AM  
Sep-14-21 08:19AM  
Sep-03-21 11:31AM  
Sep-02-21 04:01PM  
Aug-26-21 07:36AM  
Aug-20-21 04:02PM  
11:57AM  
06:36AM  
05:54AM  
Aug-19-21 04:01PM  
Aug-15-21 11:05AM  
Aug-06-21 04:31PM  
Aug-05-21 11:41AM  
Aug-04-21 05:55PM  
04:01PM  
Aug-02-21 04:50PM  
Jul-28-21 03:04PM  
Jul-22-21 11:40AM  
Jul-16-21 08:00AM  
Jul-15-21 04:01PM  
Jun-28-21 09:31AM  
Jun-15-21 08:00AM  
Jun-04-21 03:06PM  
11:32AM  
07:00AM  
Jun-02-21 09:40AM  
May-31-21 06:01AM  
May-25-21 04:01PM  
May-14-21 08:17AM  
May-13-21 04:01PM  
May-06-21 01:29PM  
11:01AM  
May-05-21 05:15PM  
04:01PM  
03:15PM  
Apr-29-21 08:00AM  
Apr-27-21 04:31PM  
Apr-15-21 12:29PM  
Apr-06-21 02:00PM  
Apr-02-21 06:20AM  
Mar-26-21 11:31AM  
Mar-25-21 07:00AM  
05:55AM  
Mar-08-21 07:00AM  
Feb-27-21 09:23AM  
01:43AM  
Feb-25-21 12:48PM  
03:30AM  
Feb-24-21 04:55PM  
04:01PM  
03:15PM  
Feb-22-21 04:01PM  
Feb-08-21 12:49AM  
Jan-29-21 06:56AM  
Jan-28-21 06:42AM  
Jan-11-21 08:02AM  
Jan-08-21 04:26PM  
09:01AM  
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors, as well as ProTmune for the treatment of hematologic malignancies and rare genetic disorders. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wolchko J ScottPresident and CEOApr 22Option Exercise2.7010,00027,000441,546Apr 25 04:11 PM
Wolchko J ScottPresident and CEOApr 22Sale34.5910,000345,911431,546Apr 25 04:11 PM
Wolchko J ScottPresident and CEOApr 21Option Exercise2.7030,00081,000461,546Apr 25 04:11 PM
Wolchko J ScottPresident and CEOApr 21Sale35.0030,0001,049,881431,546Apr 25 04:11 PM
Chu Yu-WayeChief Medical OfficerApr 19Sale35.374,062143,673151,033Apr 21 04:04 PM
TAHL CINDYGeneral Counsel and SecretaryApr 01Option Exercise5.2225,000130,520214,151Apr 04 05:01 PM
TAHL CINDYGeneral Counsel and SecretaryApr 01Sale38.8525,000971,250189,151Apr 04 05:01 PM
Valamehr BahramChief R&D OfficerMar 14Option Exercise2.7325,00068,250204,834Mar 15 04:27 PM
Valamehr BahramChief R&D OfficerMar 14Sale31.0725,000776,733179,834Mar 15 04:27 PM
MENDLEIN JOHNDirectorMar 10Option Exercise1.6331,56251,446191,017Mar 11 04:58 PM
MENDLEIN JOHNDirectorMar 10Sale35.0231,5621,105,200159,455Mar 11 04:58 PM
Wolchko J ScottPresident and CEOJan 21Option Exercise2.7010,00027,000441,546Jan 24 04:36 PM
Wolchko J ScottPresident and CEOJan 21Sale38.0210,000380,200431,546Jan 24 04:36 PM
Wolchko J ScottPresident and CEOJan 20Option Exercise2.7330,00081,900461,546Jan 24 04:36 PM
Wolchko J ScottPresident and CEOJan 20Sale40.2130,0001,206,300431,546Jan 24 04:36 PM
Wolchko J ScottPresident and CEOJan 11Sale48.6814,566709,027431,546Jan 13 04:09 PM
TAHL CINDYGeneral Counsel and SecretaryJan 11Sale48.535,419262,975155,849Jan 13 04:08 PM
Dulac Edward J IIIChief Financial OfficerJan 11Sale48.451,77085,757108,634Jan 13 04:06 PM
Valamehr BahramChief R&D OfficerJan 11Sale48.504,570221,655146,532Jan 13 04:07 PM
Chu Yu-WayeSenior VP Clinical DevelopmentJan 11Sale48.513,965192,340121,793Jan 13 04:05 PM
Wolchko J ScottPresident and CEOJan 10Sale46.8634,1561,600,534446,112Jan 12 04:07 PM
TAHL CINDYGeneral Counsel and SecretaryJan 10Sale46.437,738359,313161,268Jan 12 04:06 PM
Valamehr BahramChief R&D OfficerJan 10Sale46.385,596259,558151,102Jan 12 04:05 PM
TAHL CINDYGeneral Counsel and SecretaryJan 03Option Exercise6.5550,000327,500219,006Jan 04 04:03 PM
TAHL CINDYGeneral Counsel and SecretaryJan 03Sale59.3450,0002,966,853169,006Jan 04 04:03 PM
Dulac Edward J IIIChief Financial OfficerDec 20Option Exercise35.5214,437512,802126,381Dec 21 04:08 PM
Dulac Edward J IIIChief Financial OfficerDec 20Sale60.0015,977958,620110,404Dec 21 04:08 PM
Valamehr BahramChief R&D OfficerDec 13Option Exercise2.7325,00068,250181,698Dec 14 04:18 PM
Valamehr BahramChief R&D OfficerDec 13Sale47.6625,0001,191,406156,698Dec 14 04:18 PM
Chu Yu-WayeSenior VP Clinical DevelopmentDec 10Option Exercise16.327,500122,400133,258Dec 13 05:53 PM
Chu Yu-WayeSenior VP Clinical DevelopmentDec 10Sale51.467,500385,948125,758Dec 13 05:53 PM
Wolchko J ScottPresident and CEONov 18Option Exercise2.7020,00054,000413,793Nov 22 05:45 PM
Wolchko J ScottPresident and CEONov 18Sale54.2720,0001,085,400393,793Nov 22 05:45 PM
Wolchko J ScottPresident and CEOOct 22Option Exercise3.0630,00091,670423,793Oct 25 04:04 PM
Wolchko J ScottPresident and CEOOct 22Sale58.8830,0001,766,400393,793Oct 25 04:04 PM
Wolchko J ScottPresident and CEOOct 21Option Exercise2.7330,00081,900423,793Oct 25 04:04 PM
Wolchko J ScottPresident and CEOOct 21Sale60.2230,0001,806,560393,793Oct 25 04:04 PM
TAHL CINDYGeneral Counsel and SecretaryOct 01Option Exercise6.5550,000327,500158,048Oct 04 04:12 PM
TAHL CINDYGeneral Counsel and SecretaryOct 01Sale58.8350,0002,941,462108,048Oct 04 04:12 PM
Dulac Edward J IIIChief Financial OfficerSep 28Option Exercise35.5217,325615,38471,864Sep 30 04:14 PM
Dulac Edward J IIIChief Financial OfficerSep 28Sale62.5319,4601,216,83452,404Sep 30 04:14 PM
Valamehr BahramChief Development OfficerSep 13Option Exercise2.7325,00068,250120,740Sep 14 04:01 PM
Valamehr BahramChief Development OfficerSep 13Sale66.2925,0001,657,25795,740Sep 14 04:01 PM
Wolchko J ScottPresident and CEOAug 19Option Exercise4.8320,00096,700413,793Aug 20 04:02 PM
Dulac Edward J IIIChief Financial OfficerAug 19Sale88.263,474306,60254,539Aug 20 04:01 PM
Wolchko J ScottPresident and CEOAug 19Sale88.0120,0001,760,204393,793Aug 20 04:02 PM
Wolchko J ScottPresident and CEOJul 23Option Exercise4.1430,000124,100423,793Jul 26 04:05 PM
Wolchko J ScottPresident and CEOJul 23Sale85.2830,0002,558,538393,793Jul 26 04:05 PM
Wolchko J ScottPresident and CEOJul 22Option Exercise2.7330,00081,900423,793Jul 26 04:05 PM
Wolchko J ScottPresident and CEOJul 22Sale86.0530,0002,581,575393,793Jul 26 04:05 PM
Valamehr BahramChief Development OfficerJun 14Option Exercise2.8425,00070,997120,740Jun 16 04:26 PM
Valamehr BahramChief Development OfficerJun 14Sale89.3225,0002,233,04595,740Jun 16 04:26 PM
Wolchko J ScottPresident and CEOMay 20Option Exercise4.8320,00096,700413,793May 24 04:01 PM
Wolchko J ScottPresident and CEOMay 20Sale77.1620,0001,543,292393,793May 24 04:01 PM